Congenital: Hypoplastic Left Heart Syndrome
COVID-19 as a confounding factor in a child submitted to staged surgical palliation of hypoplastic left heart syndrome: One of the first reports of SARS-CoV-2 infection in patients with congenital heart disease
In December 2019, in the province of Wuhan, China, authorities identified an outbreak of pneumonia caused by a novel coronavirus, colloquially referred at COVID-19. The virus has now spread worldwide, reaching pandemic proportions.1 Although adult patients with cardiovascular comorbidities are at increased risk of progressing with the severe form of the disease,2 it is not known whether the same holds true for children with congenital heart disease (CHD). Furthermore, both the incidence of infection and severity of disease seem to be much lower in children than in adults.The interannular bridge: A new technique for the management of tricuspid regurgitation in hypoplastic left heart syndrome
For patients with hypoplastic left heart syndrome (HLHS), it is essential to control moderate to severe tricuspid regurgitation (TR) so that the Norwood procedure can be tolerated. Because of the vulnerability and future growth potential of the valve leaflet, it is difficult to adopt a conventional procedure for immobilizing the leaflets and annulus. We report here a case in which we used the interannular bridge technique to control central TR in an infant with HLHS who had undergone the Norwood procedure.
